Indivior Pharmaceuticals, Inc. reported results for the quarter ended 2026 with revenue of $343M and diluted EPS of $0.98, reflecting year-over-year improvement driven by SUBLOCADE volume and mix.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$343M$302M13.6% | Net income²$122M$18M577.8% | Diluted EPS³$0.98$0.14600% |
¹ Reported as “Net revenue”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was led by the U.S., where net revenue rose 17% for the three-month period and 20% year-to-date, driven primarily by higher SUBLOCADE volume and a favorable product mix.
- SUBLOCADE continued to gain share, representing roughly 74% of net revenue; total SUBLOCADE revenue was up 21% for the quarter and 26% year-to-date.
- Rest‑of‑World revenue declined about (7%) for the quarter following exits from certain non‑U.S. markets; this trend is expected to continue.
- SG&A and R&D expenses were reduced through headcount cuts and program cessations; R&D activity on the pipeline was halted, lowering near‑term spend.
- Capital investment continues for a new Raleigh manufacturing facility, with an additional $10–15M of capex expected in H2 2026 to support SUBLOCADE supply.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.